ABOUT THIS EPISODE
Multiple myeloma is a heterogenous plasma cell disorder that contains a small fraction of clonogenic stem cells, just like many other cancers. Although the exact nature and biological properties of these cells remain elusive, multiple myeloma stem cells (MMSCs) have pronounced drug resistance and are believed to be the root cause of failure of many myeloma management therapies. We are talking to Dr William Matsui of Johns Hopkins University School of Medicine to learn about the latest research on multiple myeloma stem cells and their role in novel drug development to treat multiple myeloma.
English
United States
TRANSCRIPT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
OTHER EPISODES IN THIS PODCAST
ASCO 2019 concluded on June 4th and we are excited about Multiple Myeloma updates from the largest gathering of oncologists, researchers and health professionals. The myeloma panel is talking to Dr. Joseph Mikhael, Professor, Applied Cancer Research and Drug Discovery, Translational Genomics Resear…
Intro call with Dr. Craig Hofmeister from Winship Cancer Institute.
Precision medicine is an emerging approach in cancer treatment and prevention. It is a shift away from a one-size-fits-all approach and requires sharing of information across research settings and community. Precision Medicine's central principle revolves around the ability to identify personal gen…
Immunotherapy is a type of cancer treatment that helps your immune system fight cancer. Several types of immunotherapy are used to treat cancer. These treatments either re-engineer the immune cells or empower them to launch an attack on the cancer directly. Immunotherapy has led to remarkable resul…
Disclaimer: The podcast and artwork embedded on this page are from CureTalks, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.
EDIT
Thank you for helping to keep the podcast database up to date.
